BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease

By: via Benzinga
BioTime, Inc. (NYSE MKT: BTX) today announced that the clinical-grade human Embryonic Stem (hES) cell lines from BioTime's wholly-owned ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.